Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending July 2015. The document serves as a notification of transactions involving Directors and Persons Discharging Managerial Responsibilities (PDMRs) in accordance with DTR 3.1.4R(1)(a).
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is strictly a disclosure of insider share acquisitions and does not contain financial performance data.
Material Changes
No material changes to financial performance or operations are reported in this document. The only reported activity is the acquisition of GSK Ordinary Shares by specific executives on July 9, 2015, at a price of 1368.97 pence per share through the GSK ShareReward Plan.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or discussion of contingencies. It is a routine regulatory disclosure of director shareholdings.
Important Facts for Investors
- Transaction Date: July 9, 2015.
- Share Price: 1368.97 pence per Ordinary Share.
- Participants: Sir Andrew Witty, Mr R G Connor, Mr S Dingemans, Mr N Hirons, Mr D S Redfern, Ms C Thomas, Mr P C Thomson, Dr P J T Vallance, Ms E Walmsley, and Mrs V A Whyte.
- Acquisition Method: Shares were acquired via the GSK ShareReward Plan, consisting of both personal contribution and matching GSK contribution elements.
- Volume: Most directors acquired 9 shares under each element; Mr N Hirons acquired 10 shares under each element.